Abstracts tagged "African-Americans"

Abstract Number: 362 • 2019 ACR/ARP Annual Meeting
Methods to Efficiently Recruit Minority Patients with Gout for Clinic-Based Registries
Giovanni Adami¹, Giovanna Rosas ², Joshua Melnick ³, Jeffrey Foster ², Elizabeth Rahn ², Amy Mudano ⁴, Jeffrey Curtis ², Tony Merriman ⁵, S Louis Bridges ⁴ and Kenneth Saag ², ¹University of Verona, Verona, Italy, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmimgham, AL, ⁴University of Alabama at Birmingham, Birmingham, ⁵University of Otago, Birmingham, AL
Background/Purpose: Gout is frequently misdiagnosed and/or miscoded, making approaches to identifying eligible patients for observational and interventional studies more challenging. Ethnic and racial minorities are…
Abstract Number: 805 • 2019 ACR/ARP Annual Meeting
Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities
Shivani Garg¹, Christie Bartels ¹, Cristina Drenkard ², Gaobin Bao ² and S Sam Lim ², ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Emory University, Atlanta, GA
Background/Purpose: SLE is an independent risk factor for premature cardiovascular disease (CVD) and afflicts African Americans (AA’s) 3 times more than whites. Two predominantly white…
Abstract Number: 1050 • 2019 ACR/ARP Annual Meeting
Genome-Wide DNA Methylation Signatures in Classical Monocytes from African Ancestry Patients with Systemic Sclerosis
Peter Allen¹, Jena Wirth ², Nathan Wilson ², Jim Oates ³, Melissa Cunningham ², Devin Absher ⁴ and Paula Ramos ², ¹University of Alabama at Birmingham, Birmingham, AL, ²Medical University of South Carolina, Charleston, ³Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC, ⁴HudsonAlpha Institute for Biotechnology, Huntsville, AL
Background/Purpose: Systemic sclerosis (SSc) is a rare, fibrotic autoimmune disorder characterized by cutaneous and visceral fibrosis, immune dysregulation, and vasculopathy. It disproportionately affects individuals of…
Abstract Number: 1828 • 2019 ACR/ARP Annual Meeting
Avascular Necrosis Is Associated with APOL1 Variants in African Americans with Systemic Lupus Erythematosus
Kevin Yip¹, Elizaveta Efuni ², Yingzhi Qian ¹, Robert Clancy ³, Jill Buyon ² and Ashira Blazer ¹, ¹New York University School of Medicine, New York City, ²New York University School of Medicine, New York, NY, ³New York University School of Medicine, New York
Background/Purpose: African Americans (AA) with systemic lupus erythematous (SLE) are at higher risk for both renal disease and avascular necrosis (AVN). The two Apolipoprotein L1…
Abstract Number: 1830 • 2019 ACR/ARP Annual Meeting
Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth Volkmann¹, Virginia Steen ², Ning Li ³, Michael Roth ⁴, Philip Clements ³, Dinesh Khanna ⁵, Daniel Furst ⁶, Shervin Assassi ⁷, Grace Kim ³, Jonathan Goldin ³, Robert Elashoff ³ and Donald Tashkin ³, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²Georgetown University, Washington, D.C., USA, Georgetown, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁶University of California, Los Angeles, CA, ⁷Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX
Background/Purpose: Observational studies have demonstrated that African American (AA) patients with systemic sclerosis (SSc) have a more unfavorable prognosis compared with non-AA. However, no studies…
Abstract Number: 2217 • 2019 ACR/ARP Annual Meeting
DEXA Does Not Accurately Reflect FRAX Score in Patients with Autoimmune Disease on Corticosteroids
Sima Terebelo¹, Madina Abduraimova ¹, Latoya Freeman-Beman ¹, Naureen Kabani ², Joshy Pathiparampil ¹, Olga Dvorkina ² and Ellen M Ginzler ³, ¹SUNY Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, ³State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: Osteoporosis (OP) is a problem in the aging population. Patients with autoimmune disease are at increased risk for OP given their history of steroid…
Abstract Number: 2769 • 2018 ACR/ARHP Annual Meeting
A Single Center Experience of Temporal Artery Biopsies Performed in 30 African American Patients
Ammar Haikal¹, Garth Fraga², Jason Springer¹ and Mehrdad Maz³, ¹Department of Internal Medicine, The University of Kansas Medical Center, Division of Allergy, Clinical Immunology & Rheumatology, Kansas City, KS, ²The University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, Kansas City, KS, ³Allergy, Clinical Immunology, and Rheumatology, Division of Allergy, Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Giant cell arteritis (GCA) is a systemic vasculitis of large and medium-sized arteries mostly reported in Caucasians (CCs) over 50 y.o. There is limited…
Abstract Number: 281 • 2018 ACR/ARHP Annual Meeting
Development of an African American Lupus Community-Based Patient and Provider Education Program: Lupus Conversations
Karen Mancera-Cuevas¹, Courtnie Phillip², Cianna Leatherwood³, Chase Correia⁴, James Brucker⁴, Elmer Freeman⁵, Gail Granville⁶, Kay Mimms⁷, Patricia Canessa⁸, Candace H. Feldman³ and Rosalind Ramsey-Goldman⁹, ¹Rheumatology, Northwestern University, Chicago, IL, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Northwestern University, Chicago, IL, ⁵Northeastern University, Boston, MA, ⁶Women of Courage, Inc., Boston, MA, ⁷Lupus Society of Illinois, Chicago, IL, ⁸Illinois Public Health Association, Springfield, IL, ⁹FSM, Northwestern University, Chicago, IL
Background/Purpose: African Americans (AA) with lupus experience severe manifestations and outcomes, and a long journey to diagnosis and care. We developed and tested evidence-based, culturally…
Abstract Number: 1094 • 2018 ACR/ARHP Annual Meeting
Endogenous Ifnβ Production Is Required for Efficient BCR Crosslinking and Survival of SLE B Cells
John D. Mountz¹, Shanrun Liu², PingAr Yang³, Qi Wu⁴, Bao Luo⁵, W. Winn Chatham⁶ and Hui-Chen Hsu⁴, ¹University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL, ²Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Medcine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Increased type I interferon (IFN) has been shown to affect survival and activation of B cells in SLE. This study investigated novel mechanisms of…
Abstract Number: 1120 • 2018 ACR/ARHP Annual Meeting
Strong HLA and Novel Non-HLA Associations Identified By Auto-Antibody Subset Analysis of African Americans with Scleroderma from the Genome Research in African American Scleroderma Patients Cohort
Pravitt Gourh¹, Elaine F. Remmers², Theresa Alexander³, Steven Boyden⁴, Nadia D. Morgan⁵, Ami A. Shah⁶, Maureen D. Mayes⁷, Ayo Doumatey², Amy Bentley², Daniel Shriner⁸, Robyn T. Domsic⁹, Thomas A. Medsger Jr.¹⁰, Virginia D. Steen¹¹, Paula S. Ramos¹², Rick Silver¹³, Benjamin D. Korman¹⁴, John Varga¹⁵, Elena Schiopu¹⁶, Dinesh Khanna¹⁷, Vivien Hsu¹⁸, Jessica K. Gordon¹⁹, Lesley Ann Saketkoo²⁰, Heather Gladue²¹, Brynn Kron²², Lindsey A. Criswell²², Chris T. Derk²³, S. Louis Bridges Jr.²⁴, Victoria Shanmugam²⁵, Kathleen D. Kolstad²⁶, Lorinda Chung²⁷, Reem Jan²⁸, Elana J. Bernstein²⁹, Avram Goldberg³⁰, Marcin Trojanowski³¹, Suzanne Kafaja³², Kathleen Maksimowicz-McKinnon³³, Settara C Chandrasekharappa², Adebowale Adeyemo², Charles Rotimi², Fredrick M. Wigley³⁴, Francesco Boin³⁵ and Daniel L. Kastner³⁶, ¹NIAMS-Rheumatology, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders, Bethesda, MD, ⁵Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁸National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, MD, ⁹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁰University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ¹²Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, ¹³Rheumatology, Medical University of SC, Charleston, SC, ¹⁴Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ¹⁵Northwestern University, Chicago, IL, ¹⁶University of Michigan, Ann Arbor, MI, ¹⁷Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁸Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ¹⁹Rheumatology, Hospital for Special Surgery, New York, NY, ²⁰Tulane, New Orleans, LA, ²¹Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²²University of California San Francisco, San Francisco, CA, ²³Rheumatology, University of Pennsylvania, Philadelphia, PA, ²⁴Clinical Immunology & Rheum, Univ of Alabama, Birmingham, AL, ²⁵Rheumatology, The George Washington University, Washington, DC, ²⁶Rheumatology, Stanford University Medical Center, Stanford, CA, ²⁷Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²⁸Medicine, Rheumatology, University of Chicago, Chicago, IL, ²⁹Rheumatology, Columbia University, New York, NY, ³⁰NYU Langone Medical Center, New York, NY, ³¹Boston University, Boston, MA, ³²David Geffen School of Medicine, UCLA, Los Angeles, CA, ³³Rheumatology, Henry Ford Hospital, Detroit, MI, ³⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³⁵Rheumatology, University California, San Francisco, San Francisco, CA, ³⁶Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Anti-fibrillarin (nucleolar, AFA) and anti-topoisomerase I (ATA) autoantibodies are specific to systemic sclerosis (SSc) and are common in African Americans (AA). These autoantibodies define…
Abstract Number: 1292 • 2018 ACR/ARHP Annual Meeting
HLA-B*58:01 Genotype and the Risk of Allopurinol-Associated Severe Cutaneous Adverse Reactions in a Predominately Black or African American Population with Advanced Chronic Kidney Disease
Sarah Ford¹, Pamela Kimball¹, Gaurav Gupta¹ and Nehal Shah², ¹Virginia Commonwealth University, Richmond, VA, ²Medicine/Rheumatology, Virginia Commonwealth University, Richmond, VA
Background/Purpose: Allopurinol is the first line urate lowering drug used for treatment of gout. Its most feared side effect includes development of hypersensitivity drug reactions…
Abstract Number: 1842 • 2018 ACR/ARHP Annual Meeting
Implementation of an African American Popular Opinion Leader Model to Address Disparities in Lupus Knowledge and Care
Courtnie Phillip¹, Cianna Leatherwood², Elmer Freeman³, Gail Granville⁴, Gayna Sealy⁵, Toni Wiley⁵, Chase Correia⁶, Karen Mancera-Cuevas⁷, Patricia Canessa⁸, Rosalind Ramsey-Goldman⁹ and Candace H. Feldman², ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Northeastern University, Boston, MA, ⁴Women of Courage, Inc., Boston, MA, ⁵Sportsmen's Tennis and Enrichment Center, Dorchester, MA, ⁶Northwestern University, Chicago, IL, ⁷Rheumatology, Northwestern University, Chicago, IL, ⁸Illinois Public Health Association, Springfield, IL, ⁹FSM, Northwestern University, Chicago, IL
Background/Purpose: Lupus is a chronic, autoimmune disease that disproportionately affects African American individuals. Community-based educational interventions that capitalize on rich social networks can be used…
Abstract Number: 1943 • 2018 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants Associate with Poor Renal Outcomes, Damage Accrual, and Death: A Prospective Ghanaian SLE Cohort
Ashira Blazer¹, Ida Dzifa Dey², Margaret Reynolds³, Festus Ankrah³, Nancyanne Schmidt⁴, Robert M. Clancy⁵ and Jill P. Buyon⁶, ¹Internal Medicine Division of Rheumatology, NYU School of Medicine, New York, NY, ²Department of Medicine, Rheumatology Unit, School of Medicine and Dentistry,University of Ghana, Accra, Ghana, ³Internal Medicine, The University of Ghana, Accra, Ghana, ⁴Internal Medicine, New York University School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Two Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2, are enriched in ancestrally African populations due to a conferred superior resistance to Trypanosoma…
Abstract Number: 2733 • 2018 ACR/ARHP Annual Meeting
From a Myth to a Menace: Increased Disease Severity and Poor Outcomes in an Urban Cohort of African-American Patients with ANCA-Associated Vasculitis
Kathleen Maksimowicz-McKinnon¹, Philip McCarthy², Sandeep Soman³ and John McKinnon³, ¹Rheumatology, Henry Ford Hospital, Detroit, MI, ²Michigan State University College of Osteopathic Medicine, East Lansing, MI, ³Henry Ford Hospital, Detroit, MI
Background/Purpose: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic inflammatory disorder frequently associated with significant disability and morbidity, which may lead to end-stage renal disease…
Abstract Number: 919 • 2017 ACR/ARHP Annual Meeting
HLA Type Imputation in the Genome Research in African American Scleroderma Patients (GRASP) Cohort Reveals Strong Associations of African Ancestry MHC Class II Types with Scleroderma and Lack of Class I HLA Type Associations
Elaine F. Remmers¹, Pravitt Gourh², Steven Boyden³, Nadia D. Morgan⁴, Ami A. Shah⁴, Adebowale Adeyemo¹, Amy Bentley¹, Mary A. Carns⁵, Settara C. Chandrasekharappa¹, Lorinda Chung⁶, Lindsey A. Criswell⁷, Chris T. Derk⁸, Robyn T. Domsic⁹, Ayo Doumatey¹, Heather Gladue¹⁰, Avram Goldberg¹¹, Jessica K. Gordon¹², Vivien M Hsu¹³, Reem Jan¹⁴, Dinesh Khanna¹⁵, Maureen D. Mayes¹⁶, Thomas A. Medsger Jr.¹⁷, Paula S. Ramos¹⁸, Marcin A. Trojanowski¹⁹, Lesley A. Saketkoo²⁰, Elena Schiopu¹⁵, Victoria K. Shanmugam²¹, Daniel Shriner¹, Richard M. Silver²², Virginia D. Steen²³, Antonia Valenzuela²⁴, John Varga²⁵, Charles Rotimi¹, Fredrick M. Wigley²⁶, Francesco Boin²⁷ and Daniel L. Kastner²⁸, ¹National Institutes of Health (NIH), National Human Genome Research Institute, Bethesda, MD, ²NIAMS-Rheumatology, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ³National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders, Bethesda, MD, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁶Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁷Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁸Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁰Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹¹NYU Langone Medical Center, New York, NY, ¹²Rheumatology, Hospital for Special Surgery, New York, NY, ¹³University of Medicine and Dentistry of New Jersey--Robert Wood Johnson Medical School, New Brunswick, NJ, ¹⁴Medicine, Rheumatology, University of Chicago, Chicago, IL, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶University of Texas McGovern Medical School, Houston, TX, ¹⁷Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁸Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, ¹⁹Boston University School of Medicine, Boston, MA, ²⁰Rheumatology, Tulane University School of Medicine, New Orleans, LA, ²¹Rheumatology, The George Washington University, Washington, DC, ²²Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ²³Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ²⁴Stanford University School of Medicine, Stanford, CA, ²⁵Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ²⁶Rheum Div/Mason F Lord, Johns Hopkins University, Baltimore, MD, ²⁷Rheumatology, University California, San Francisco, San Francisco, CA, ²⁸Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: The Genome Research in African American Scleroderma Patients (GRASP) consortium was created to obtain a collection of African American (AA) scleroderma patients to facilitate…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].